Sign in
Taking peoplePhase 3

Montelukast for painful erosive osteoarthritis of the hands

Tests montelukast against placebo for hand pain in erosive hand osteoarthritis.

Key facts

Who runs it
Farmalider S.A.
Where
Florence, Rome, Turin, and Velletri RM, ItalySee the 5 sitesAlso in 2 other countries, 16 sites
Registry title
RANDOMISED, MULTICENTRE, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MONTELUKAST VS. PLACEBO IN PATIENTS WITH EROSIVE/INFLAMMATORY OSTEOARTHRITIS OF THE HANDS. MOTHER Study.
Status
Recruiting
Phase
Phase 3
People taking part
160 people, planned
Started
30 Jan 2026
Expected to end
22 Jun 2027
Type of study
Interventional
Record updated
13 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with active erosive osteoarthritis of the finger joints and strong hand pain. It compares montelukast with placebo (a dummy pill).

Age
18 years or older
Sex
All sexes
Disease stage
Erosive osteoarthritis of the finger joints with clear signs of activity (Anandarajah criteria). Pain at rest in the worse hand of at least 50 mm on a pain scale (VAS). Some trouble lifting a full bottle with that hand (score ≥1 on FIHOA question 4).
Earlier treatment
No corticosteroids (oral or injected) in the 4 weeks before the start. No methotrexate, hydroxychloroquine or SYSADOAs in the 12 weeks before. No hyaluronic acid injection into the study hand in the 24 weeks before. No NSAIDs, painkillers other than paracetamol, or colchicine in the 7 days before. No biological anti-rheumatic drugs.

Main reasons for not taking part

  • Fibromyalgia, chronic fatigue syndrome, or other joint diseases such as rheumatoid arthritis, gout or psoriasis
  • Cannot have an MRI scan (for example pacemaker, claustrophobia, weight over 120 kg (265 lb)), or BMI ≥ 35 kg/m2
  • Serious illness such as severe heart, liver or kidney disease, active cancer, or a weak immune system
  • Pregnant or breastfeeding women
  • Physical therapy or rehabilitation during the trial, or surgery planned during the trial

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Patients who provide written informed consent (IC) and are able to comply with all scheduled visits and procedures required by the study
  • Patients ≥ 18 years at the screening visit
  • Patients with erosive osteoarthritis of the interphalangeal joints of the hand with significant clinical activity according to Anandarajah criteria (Anandarajah, A. 2010)
  • Patients with VAS pain at rest of the most affected hand ≥ 50 mm at baseline visit
  • Patients with repercussion in functionality of the most affected hand evaluated with a score ≥1 in the question number 4 (Are you able to lift a full bottle with the hand?) of the FIHOA questionnaire at baseline visit

Who cannot take part

  • History of drug or alcohol abuse during the 12 months prior to the baseline visit
  • Patient with a history of concurrent rheumatic articular diseases (history and/or current presence of signs) that could lead to a misinterpretation or interfere in the evaluation of efficacy in pain, such as chondrocalcinosis, Paget's disease of the ipsilateral extremity in relation to the affected hand, rheumatoid arthritis, aseptic osteonecrosis, gout, septic arthritis, ochronosis, acromegaly, hemochromatosis, Wilson's disease, osteochondromatosis, seronegative spondyloarthropathy, mixed connective tissue disease, collagen vascular disease, psoriasis and disease Inflammatory bowel (Crohn's disease or Ulcerative Colitis)
  • Patient taking corticosteroids (oral or injectable) within 4 weeks prior to the baseline visit, or methotrexate, hydroxychloroquine or SYSADOAs (Slow-Acting Drugs for the Symptomatic Treatment of Osteoarthritis) within 12 weeks prior to the baseline visit
  • Patients who have used intra-articular hyaluronic acid (in the study hand) during the 24 weeks prior to the baseline visit
  • Patient being treated with any other medication contraindicated due to risk of interactions with study medication
  • Patient being treated with other disease-modifying anti-rheumatic biological drugs
  • Patients undergoing physical therapy or active physical rehabilitation (individual or group) treatment, are exposed to electrotherapy procedures or physical therapies, including specifically: Magnetotherapy, Therapeutic Ultrasound, Transcutaneous Electrical Stimulation (TENS), during the entire period of study participation
  • Patient being treated with NSAIDs and/or analgesics (except paracetamol) or colchicine within 7 days prior to the baseline visit. The use of paracetamol will be allowed up to 24 hours prior to the start of study treatment
  • Patient currently included in or who have participated in a clinical trial with medicines or health products in the 3 months prior to the baseline visit
  • Patients with scheduled surgery during the clinical trial
  • History of fibromyalgia and/or chronic fatigue syndrome
  • Patients with any contraindication related to the performance of the MRI test, including: • Pacemakers or neurostimulators, • Metal plates or fragments not attached to the bone in risk areas, newly implanted heart valves or intracranial clips. • Claustrophobia. • Weight more than 120 kg. • Intolerance to paramagnetic contrast
  • Patient with pathologies that according to medical criteria discourage their participation in the study, such as severe heart disease, liver failure, kidney failure, active malignancies, poorly controlled endocrine-metabolic diseases, coagulopathies, active gastrointestinal ulceration, active infection, epilepsy, and immunocompromised patients
  • Patient with poorly controlled neuropsychiatric diseases evaluated with a score ≥ 10 in PHQ-9 questionnaire or score diferent than 0 in question 9 “Thoughts that you would be better off dead or of hurting yourself in some way”
  • Patient with a history of allergy or hypersensitivity to the study medication, rescue medication or any of its excipients
  • Patient intolerant to study medication due to galactose intolerance, lactase insufficiency, or glucose-galactose malabsorption
  • Women of childbearing age and sexually active (excluded from this definition are women whose date of last menstruation is greater than one year from inclusion in this study and those who have undergone a tubal ligation or hysterectomy), who do not agree to take acceptable contraceptive measures during the clinical trial. Contraceptive measures include barrier methods, hormonal contraception, intrauterine device (IUD), or sexual abstinence. The investigator is responsible for determining whether the subject has adequate birth control for study participation
  • Patients who, in the opinion of the investigator, are unable or not willing to comply with study and follow-up procedures
  • Patient with a BMI ≥ 35 kg/m2
  • Pain in another part of the body that could interfere with the evaluation and results of the study according to investigator criteria
  • Patient undergoing radioactive synoviorthesis (in the study hand)
  • Pregnant or lactating women

Where in Italy

Also in 2 other countries, 16 sites

  • Azienda Ospedaliero-Universitaria CareggiFlorence, ItalyNot yet recruiting
  • Azienda Ospedaliero-Universitaria Policlinico Umberto IRome, ItalyNot yet recruiting
  • Provincia Religiosa Di S.Pietro Dell' Ordine Ospedaliero Di San Giovanni Di Dio FatebenefratelliRome, ItalyNot yet recruiting
  • Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di TorinoTurin, ItalyNot yet recruiting
  • Ospedale Civile Paolo ColomboVelletri RM, ItalyNot yet recruiting

About the trial

What the trial wants to find out

The primary objective of the study is to evaluate the difference in pain intensity at rest of the most affected hand with respect to baseline pain at 24 weeks of treatment with Montelukast xx mg, compared to placebo, in patients with erosive hand osteoarthritis (EHOA), using the Visual Analogue Scale (VAS).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
RANDOMISED, MULTICENTRE, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MONTELUKAST VS. PLACEBO IN PATIENTS WITH EROSIVE/INFLAMMATORY OSTEOARTHRITIS OF THE HANDS. MOTHER Study.
Plain-language title
Montelukast for painful erosive osteoarthritis of the handsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
13 August 2026